Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira in very old patients with type 2 diabetes
NCT04190160Completed
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM). Primary endpoints: Control, Autonomy, Self-realization and Pleasure at 6 months and Diabetes Treatment Satisfaction at 6 months. Started Nov 2018; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04190160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190160.